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OBJECTIVE—Glucose-stimulated islet insulin or C-peptide se-
cretion experiments are a fundamental tool for studying and
assessing islet function. The goal of this work was to develop
Ab-based ﬂuorescent homogenous sensors that would allow
rapid, inexpensive, near-instantaneous determinations of insulin
and C-peptide levels in biological samples.
RESEARCH DESIGN AND METHODS—Our approach was to
use molecular pincer design (Heyduk et al., Anal Chem 2008;80:
5152–5159) in which a pair of antibodies recognizing nonover-
lapping epitopes of the target are modiﬁed with short
ﬂuorochrome-labeled complementary oligonucleotides and are
used to generate a ﬂuorescence energy transfer (FRET) signal in
the presence of insulin or C-peptide.
RESULTS—The sensors were capable of detecting insulin and
C-peptide with high speciﬁcity and with picomolar concentration
detection limits in times as short as 20 min. Insulin and C-peptide
levels determined with the FRET sensors showed outstanding
correlation with determinations performed under the same con-
ditions with enzyme-linked immunosorbent assay. Most impor-
tantly, the sensors were capable of rapid and accurate
determinations of insulin and C-peptide secreted from human or
rodent islets, verifying their applicability for rapid assessment of
islet function.
CONCLUSIONS—The homogeneous, rapid, and uncomplicated
nature of insulin and C-peptide FRET sensors allows rapid
assessment of -cell function and could enable point-of-care
determinations of insulin and C-peptide. Diabetes 59:2360–
2365, 2010
D
iabetes comprises a heterogeneous group of
hyperglycemic disorders. There are two major
forms of diabetes: 1) type 1 diabetes, which is
associated with an autoimmune-mediated at-
tack and destruction of pancreatic -cells resulting in
insulin deﬁciency, and 2) type 2 diabetes, which is char-
acterized by insufﬁcient insulin production or impaired
insulin action. For type 1 diabetic subjects, insulin injec-
tions are used to regulate plasma glucose levels, while
type 2 diabetic subjects are usually treated by diet, oral
agents, and insulin therapy. If uncontrolled, elevated
plasma levels of glucose increase the risk for the develop-
ment of diabetic complications such as cardiovascular
disease, kidney disease, neurological disorders, and blind-
ness. Intensive insulin therapy reduces the risk of such
complications, although there is an increased risk of
hypoglycemic episodes with this therapy, which, if severe,
can result in coma or seizures. Insulin is synthesized as a
precursor protein, proinsulin, that is processed by speciﬁc
proteases found in insulin granules to the active hormone
(containing an A and B chain connected by two disulﬁde
linkages). During the processing of insulin, the connecting
sequence (C-peptide) is also produced, and C-peptide is
released into the bloodstream with insulin at times of
insulin demand.
Glucose-stimulated insulin or C-peptide secretion by the
islets is a fundamental tool for studying and assessing islet
function. Current methodologies to determine -cell func-
tion rely on the use of radioimmunoassay or enzyme-
linked immunosorbent assay (ELISA)-based assays to
detect either insulin or C-peptide produced by -cells.
These methods are time-consuming and, in many cases,
require the use of radioactivity. Development of a speciﬁc
methodology for detecting insulin and/or C-peptide that
reduces the time required to determine -cell function
would provide a tremendous advantage over methods
currently being used. Such a methodology could also have
clinical applications, for example, as a rapid method to
characterize -cell function in the transplantation of hu-
man islets, a potential therapy for type 1 diabetic patients.
Transplantation of human islets, isolated from cadaver
donors, has been used for a number of years in an effort to
gain insulin independence in type 1 diabetic subjects;
however, this procedure has been only marginally success-
ful (1,2). Recently, the Edmonton group has described a
new protocol for the transplantation of human islets that
was successful in attaining short-term insulin indepen-
dence in seven of seven patients (3), and similar results
have been reproduced by others (4–6). One key feature of
the Edmonton protocol is the immediate transplantation
of islets after isolation. Previous protocols cultured islets
for extended periods of time in part to determine islet
viability and function prior to transplantation (7). A meth-
odology that would allow rapid assessment of glucose-
stimulated insulin secretion potentially could be used to
enhance characterization of islets before transplantation.
In a previous study, we described a new Ab-based
sensor technology that allowed simple ﬂuorescence-based
homogenous detection of target proteins (7). The goal of
this work was to determine whether this sensor design
could be adapted for rapid detection of insulin and C-
peptide and used for very rapid determination of islet
functional activity (insulin secretion). We show that our
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insulin or C-peptide produced by isolated human or rodent
islets, validating their applicability for rapid assessment of
islet quality. We believe that the uncomplicated and rapid
characteristics of our assay will allow for the deployment
of methods for insulin and C-peptide determinations in a
point-of-care setting.
RESEARCH DESIGN AND METHODS
Sensor design. Figure 1 illustrates general design of homogenous sensors for
insulin or C-peptide that is based on previously described molecular pincer
assay (7). A pair of antibodies recognizing nonoverlapping epitopes of insulin
(or C-peptide) are functionalized by attaching short complementary oligonu-
cleotides via long nanometer-scale ﬂexible linkers. Oligonucleotides are
modiﬁed with a pair of ﬂuorophores (ﬂuorescein and Cy5) that could function
as a donor and an acceptor in ﬂuorescence resonance energy transfer (FRET)
(8). In the presence of the target analyte, both antibodies will bind to the
target molecule, resulting in a large increase of the local concentration of
signaling oligonucleotides. This in turn will lead to annealing of the oligonu-
cleotides bringing the ﬂuorophores to close proximity, resulting in efﬁcient
FRET that can be used as a signal for target analyte detection.
Materials. NHS-PEO8-maleimide and Traut’s reagent were from Pierce
(Rockland, IL). Oligonucleotides were obtained either from Keck Oligonucle-
otide Synthesis Facility at Yale University or from IDT (Coralville, IA). The
following oligonucleotides were used (names in parentheses):
(A1) 5-C6-amino-TAGGTGCTCGACGCTGAC
(A2) 5-C6-amino-TAGGAGAGAGAGAGAGGA
(A3) 5-ﬂuorescein-GCTCATTGTCAGCGTCGAGCACCTA
(A4) 5-Cy5-ATGAGCTTCCTCTCTCTCTCTCCAT
A3 and A4 oligonucleotides contain short sequences (italicized) that are
used in target-induced annealing to generate FRET signal. Fluorescein and
Cy5-labeled oligonucleotides were puriﬁed by reverse-phase high-perfor-
mance liquid chromatography (9). Concentrations of oligonucleotides were
calculated from UV absorbance at 260 nm, after correction for ﬂuorophore
absorbance at 260 nm.
Monoclonal anti-human insulin antibodies (clones E6E5, D4B8, 8E2, and
3A6) were purchased from Fitzgerald Industries International, Inc. (Concord,
MA). Monoclonal anti-human C-peptide antibodies (clones 9101 and 9103)
were from BiosPaciﬁc (Emeryville, CA). Insulin and C-peptide ELISA kits
(EZH-14C and EZHCP-20C) were purchased from Millipore (Billerica, MA)
and were used according to the manufacturer’s instruction with the exception
of using our assay buffer (20 mmol/l Tris-HCl [pH 8.0], 100 mmol/l NaCl, and
10 mmol/l EDTA containing 0.2 mg/ml BSA) and standards prepared by us in
place of those provided in the ELISA kit.
Human, bovine, and porcine insulin, glucagon, insulin-like growth factor II,
human C-peptide, angiotensin I and II, and ACTH were purchased from Sigma
(St. Louis, MO). Canine and porcine C-peptide were obtained from Anaspec
(Fremont, CA), and human proinsulin was from R&D Systems (Minneapolis,
MN).
Antibody modiﬁcation. Antibodies were labeled with signaling oligonucle-
otides using a previously described procedure (7) (method “c” in Fig. 1B from
ref 7). A1 and A2 oligonucleotides were ﬁrst attached to the antibodies via
long linkers followed by annealing of A3 and A4 oligonucleotides to produce
Ab-A1/A3 and Ab-A2/A4 conjugates, respectively. The ﬁrst step of the proce-
dure involves preparation of a thiol-reactive oligonucleotide that is subse-
quently used to react with thiolated antibody. Two hundred microliters of
5-amine containing oligonucleotides (A1 or A2) at 250 mol/l in 20 mmol/l
NaH2PO4 (pH 7.4), 150 mmol/l NaCl, and 2.5 mmol/l EDTA buffer (conjugation
buffer) were mixed with 5 lo f250 mmol/l of NHS-PEO8-maleimide
dissolved in dimethylformamide. The reaction mixtures were incubated for
1–1.5 h at room temperature. Oligonucleotide was puriﬁed from the excess of
the cross-linker by ethanol precipitation in the presence of 1 mg/ml glycogen.
Precipitated oligonucleotides were dried in Speed-Vac and were stored at
20°C until they were used for antibody modiﬁcation. Antibody solutions
(50–75 l) containing 0.3–0.4 mg of the protein were run on a spin column
(Zeba, Pierce, Rockford, IL) equilibrated with the conjugation buffer. Antibod-
ies were thiolated for 1.5 h at room temperature with 40 molar excess of
Traut’s reagent added as 14 mmol/l stock solution in dimethylformamide.
The excess of Traut’s reagent was removed on a Zeba spin column equili-
brated in the conjugation buffer. The thiolated antibody was then reacted with
a 15–20 molar excess of linker-conjugated oligonucleotide (calculated assum-
ing that 50% of the oligonucleotides were conjugated with the cross-linker).
Reaction mixtures were incubated for4ha troom temperature followed by an
overnight incubation at 4°C.
Modiﬁed antibodies were puriﬁed from the excess of the oligonucleotides
by size-exclusion fast-protein liquid chromatography using a 10/30GL Super-
dex 200 column (Pharmacia) equilibrated with 10-fold–diluted 20 mmol/l Tris
(pH 8.0), 100 mmol/l NaCl, and 10 mol/l EDTA buffer. Fractions containing
modiﬁed antibodies were pooled and concentrated 10-fold in the Speed-Vac.
The protein concentration was estimated using Bradford assay. Labeling of
the antibodies with oligonucleotides was conﬁrmed (and the extent of the
labeling estimated) by analyzing the UV spectra of the puriﬁed ﬁnal product.
Observed spectra were ﬁtted by a linear combination of the spectra of free
antibody and free oligonucleotide to determine relative amounts of the protein
and oligonucleotide in the sample.
Islet isolation. Human islets were isolated from cadaver donors using
protocols approved by the IRB at the University of Alabama in Birmingham.
Rodent islets were isolated from male Sprague-Dawley rats (250–300 g) by
collagenase digestion as previously described (10).
Islets were cultured overnight in CMRL-1066 (containing 2 mmol/l
L-glutamine, 10% heat-inactivated FCS, 100 units/ml penicillin, and 100 g/ml
streptomycin) at 37°C under an atmosphere of 95% air and 5% CO2 prior to
experimentation.
Glucose-stimulated insulin secretion. The islets were washed with Krebs-
Ringer buffer (KRB) (25 mmol/l HEPES, 115 mmol/l NaCl, 24 mmol/l NaHCO3,
5 mmol/l KCl, 1 mmol/l MgCl2, 2.5 mmol/l CaCl2, and 0.1% BSA, pH 7.4)
containing 3.3 mmol/l glucose followed by preincubation for 30-min at 37°C in
KRB containing 3.3 mmol/l glucose. The islets (10 and 15 in the case of
human or rodent, respectively) were aliquoted to vials containing either KRB
with 3.3 mmol/l glucose or KRB with 16.7 mmol/l glucose and were incubated
for 60 min (human islets) (KRB with 20 mmol/l glucose and 30-min incubation
in the case of rodent islets) at an atmosphere of 95% air and 5% CO2 at 37°C.
After the incubation, the supernatant was removed and the samples were
stored frozen at 70°C until analyzed. In experiments where FRET sensors
were compared with ELISA, the samples were thawed and analyzed in parallel
by sensors and ELISA to eliminate any variability due to differences in sample
treatment.
Insulin and C-peptide determinations. All insulin and C-peptide measure-
ments were performed in 20 mmol/l Tris-HCl (pH 8.0), 100 mmol/l NaCl, and
10 mol/l EDTA containing 0.2 mg/ml BSA (assay buffer). Standard solutions
of insulin and C-peptide were prepared from stock solutions obtained by
dissolving human insulin and C-peptide (from Sigma) in assay buffer. Concen-
trations of stock solutions were assigned based on information provided by
the supplier. The standards were not calibrated to World Health Organization
reference material. Stock solutions were stored frozen in small aliquots at
70°C. No signiﬁcant differences were observed between the results obtained
with different samples of stock insulin or C-peptide solutions. When compar-
ing FRET sensors with ELISA, to eliminate variability of the results due to
potential instability of calibrators included in commercial ELISA kits, FRET
sensors and ELISA experiments were done in parallel using the same
solutions of insulin or C-peptide standards for preparation of FRET sensor or
ELISA calibration curves. Thus, ELISA was not performed exactly according
to the manufacturer’s instructions. While this may have affected somewhat the
performance of ELISA, it was important for the purpose of validating sensor
assay to perform sensor assays and ELISA under the same conditions.
Typically, for a standard curve, eight samples of insulin (or C-peptide) at
concentrations in the 0–15 nmol/l range were prepared by diluting stock
solutions in assay buffer. Standard curves for quantitative determinations
performed by ELISA were obtained by assaying 2.5–5 l of standard solutions
diluted to 60 l with the assay buffer. Standard curves using the ﬂuorescent
sensor methodology were obtained by assaying 5 l of standard solutions
diluted into 20 l of assay mix. Concentrations of insulin and C-peptide in
unknown samples were determined from the previously described calibration
curves using absorbance values (ELISA) obtained with 2.5–5 l of the samples
diluted to 60 l with the assay buffer or using ﬂuorescence values (sensors)
T 
FRET  FRET  FRET
FIG. 1. Design of homogenous sensors for detecting insulin and C-
peptide. “T” denotes a target (insulin or C-peptide).
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samples from islet secretion experiments were in modiﬁed Krebs-Ringer
bicarbonate buffer, 5 l of the buffer was included in the 20 l assay mix used
to measure calibration standards in this case. Absorbance at 450 nm of ELISA
samples was measured in 96-well plates using SpectroﬂuorPLus plate reader
(Tecan). Fluorescences of sensor mixes were measured in 20 l in 384-well
low-volume black microplates (Corning cat. no. 3676) at 25°C. Typically,
sensor assay mixtures contained (ﬁnal concentrations in 20 l) 20 and 25
nmol/l or 10 and 12.5 nmol/l of ﬂuorescein-labeled antibody and Cy5-labeled
antibody, respectively. Prior to ﬂuorescence measurements, the A1- and
A2-labeled antibodies were annealed with ﬂuorescent A3 and A4 oligonucle-
otides by incubating 100 nmol/l antibodies with equimolar amounts of A3 or
A4 for 30 min at room temperature. These 100 nmol/l stocks of labeled
antibodies were then used to prepare 2 sensor mix solutions in the assay
buffer. Appropriate volumes of samples and assay buffer were then added to
10 lo f2  assay solutions to obtain ﬁnal assay volume of 20 l that was used
for ﬂuorescence measurements.
The donor (ﬂuorescein; excitation at 485 nm, emission at 535 nm) and
sensitized acceptor emission (Cy5; excitation at 485 nm, emission at 665 nm)
signals were read with an Analyst AD plate reader (LJL Biosystems, Sunny-
vale, CA). Reaction mixtures were incubated for at least 20 min before
ﬂuorescence measurements were made (with the exception of kinetic exper-
iments, where incubation time varied).
Results of ﬂuorescence measurements were expressed as normalized
FRET signal change (FRET):
FRET  (FSA/FD)/(FSA
0/FD
0)  1 (1)
where FSA, FD, FSA
0, and FD
0 are sensitized acceptor and donor emission
intensities in the presence and absence of insulin (or C-peptide), respectively.
Buffer background was subtracted from the measured ﬂuorescence intensities
before FRET values were calculated. Using the ratio of sensitized acceptor
and donor emission intensities for calculating FRET according to Eq. 1
reduces the variability of FRET measurements due to dilution and instrumen-
tation errors. Radioimmunoassay (RIA) determinations of insulin in rat islet
secretion experiments were performed by Washington University DRTC (St.
Louis, MO).
RESULTS
We have previously demonstrated feasibility of the sensor
design illustrated in Fig. 1 using thrombin, cardiac tropo-
nin, and C-reactive proteins as models and using antibod-
ies (7) or aptamers (11) as the binders. The assay depicted
in Fig. 1 requires only adding the sample to the sensor mix
followed by a simple ﬂuorescence intensity measurement.
We thus hypothesized that, if the sensors with adequate
sensitivity and speciﬁcity could be developed for insulin or
C-peptide, they could be an extremely useful tool in rapid
assessment of islet function.
We ﬁrst prepared an insulin sensor using anti-insulin
monoclonal antibody clones E6E5 and D4B8 (Fitzgerald
Industries International). When titrated with increasing
concentrations of insulin, a robust and highly reproducible
insulin concentration–dependent FRET signal was ob-
served (Fig. 2A, gray symbols). While robust, the signal
was lower when compared with what we have previously
observed in the case of troponin or C-reactive protein (7).
We wondered if the antibody pair we selected for the
sensors was indeed the most optimal. We tested another
monoclonal antibody pair (clones 8E2 and 3A6 from
Fitzgerald Industries International, Inc.) that, according to
the manufacturer’s speciﬁcations, had higher insulin-bind-
ing afﬁnity. The sensors prepared from this antibody pair
exhibited a much better (5-fold higher) FRET signal in
the presence of insulin (Fig. 2A, black symbols). Limit of
detection was also improved substantially (from 1 nmol/l
[gray symbols] to 100 pmol/l [black symbols]). The upper
limit of detection is a function of sensor concentration
used and, thus, can be tailored to a desired value by
changing the sensor concentration (data not shown).
Analytical sensitivity (deﬁned as the ratio of the mean of
the measured concentrations to the actual concentrations)
was 1.13 	 0.13. Comparison of these two datasets ob-
tained with two pairs of monoclonal antibodies shows that
the binding afﬁnity of the antibodies that are used for
preparing the sensors is a key determinant of the perfor-
mance of the sensors.
In the next set of experiments, a sensor of similar quality
to that obtained for insulin was developed for C-peptide.
Figure 2B shows that, as in the case of insulin, a C-peptide
sensor exhibited a robust and highly reproducible C-
peptide concentration–dependent response. The esti-
mated limit of detection (50 pmol/l) was slightly better
than the limits for the insulin sensor. Analytical sensitivity
was 0.99 	 0.06.
The data shown in Fig. 3A demonstrate speciﬁcity of the
insulin sensor. While a robust response in the presence of
insulin is observed, no FRET signal was detected in the
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FIG. 2. A: Response of the insulin sensor to indicated amounts of human insulin. Experiments were performed with a sensor mixture containing
20 nmol/l ﬂuorescein-labeled antibody and 25 nmol/l of Cy5-labeled antibody. Black and gray symbols correspond to experiments performed with
sensors using 8E2/3A6 and E6E5/D4B8 antibody pairs, respectively. The average and SD of three measurements are shown. B: Response of the
human C-peptide sensor to indicated amounts of C-peptide. Experiments were performed with a sensor mixture containing 20 nmol/l
ﬂuorescein-labeled antibody and 25 nmol/l of Cy5-labeled antibody. The average and SD of three measurements are shown. FRET signals were
read after a minimum of 20 min of incubation after adding sample to the sensor mix.
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sive data regarding insulin sensor speciﬁcity is summa-
rized in supplementary Table S9 (available in an online
appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db10-0088/DC1). No signiﬁcant cross-reactiv-
ity was observed for any of the C-peptides or various
unrelated polypeptides tested. The sensor could detect
bovine, porcine, and rat insulin as well (in some cases
better) as human insulin. Partial cross-reactivity with
human proinsulin was observed. Speciﬁcity of the sensors
reﬂects speciﬁcity of the antibodies that were used to
prepare them so it could be altered by using a different set
of antibodies for sensor preparation, if available. We
expected that our sensors, because of their homogenous
nature, would allow quick, uncomplicated measurement of
insulin in a sample. Figure 3B shows the time dependence
of insulin sensor response (FRET signal) upon addition of
indicated amounts of insulin to the sensor mix. Full
response was obtained within 20 min, with 50% of the
maximum signal observed 5 min after addition of the test
sample. Data in Fig. 3B demonstrate a key feature of our
sensors, the ability to detect insulin in a very rapid manner
using a simple homogenous assay format that does not
require specialized instrumentation (all the data were
collected using a standard ﬂuorescence plate reader). The
C-peptide sensor was also highly speciﬁc, as the FRET
signal was not observed in the presence of human insulin
(Fig. 3C). More extensive data regarding C-peptide sensor
speciﬁcity are summarized in supplementary Table S10.
No signiﬁcant cross-reactivity was observed for any of the
C-peptides from other species, any insulins, or various
unrelated polypeptides tested. Partial cross-reactivity with
human proinsulin was observed. The time course of the
response of the C-peptide sensor (Fig. 3D) was very
similar to the insulin sensor requiring 20 min for the
maximal FRET signal and exhibiting 
50% of maximal
signal change after 5 min of incubation.
The data presented in Figs. 2 and 3 established the
feasibility of homogenous FRET sensors for insulin and
C-peptide. To examine the performance of these sensors
for quantitative determination of insulin and C-peptide, we
compared our sensors with standard and established
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FIG. 3. A: Speciﬁcity of insulin sensor. Response of insulin sensor to human insulin and human C-peptide is compared. Sensor mixture containing
20 nmol/l ﬂuorescein-labeled 8E2 antibody and 25 nmol/l of Cy5-labeled 3A6 antibody was used. FRET signals were read after a minimum of 20
min of incubation after adding sample to the sensor mix. B: Kinetics of insulin sensor response at indicated human insulin concentrations. Sensor
mixture containing 20 nmol/l ﬂuorescein-labeled E6E5 antibody and 25 nmol/l of Cy5-labeled D4B8 antibody was used. C: Speciﬁcity of C-peptide
sensor. Response of C-peptide sensor to human C-peptide and human insulin is compared. FRET signals were read after a minimum of 20 min of
incubation after adding sample to the sensor mix. D: Kinetics of C-peptide sensor response at indicated C-peptide concentrations. Sensor
mixtures containing 20 nmol/l ﬂuorescein-labeled antibody and 25 nmol/l of Cy5-labeled antibody were used.
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(Fig. 4). Thirty-two samples containing randomly chosen
concentrations of insulin or C-peptide (in the 0–14 nmol/l
range) were prepared in the assay buffer. The levels of
insulin (Fig. 4A) and C-peptide (Fig. 4B) in these samples
were quantiﬁed in parallel using our sensors and ELISA.
There was outstanding correlation between the two meth-
ods (R
2  0.98; Fig. 4) demonstrating the utility of FRET
sensors for quantitative determination of insulin and
C-peptide.
To conﬁrm the functionality and to examine the practi-
cal utility of our sensors, the levels of insulin and C-
peptide were determined in randomly chosen samples
from glucose-stimulated secretion experiments performed
with human islets. Thirty-two samples from secretion
experiments at low and high glucose levels were analyzed
in parallel by FRET sensors and ELISA (Fig. 5). In every
sample tested, it was possible to determine the level of
insulin (or C-peptide) using FRET sensors, showing that
the sensors could be used for measuring insulin and
C-peptide secreted at low and high glucose levels. There
was a cluster of data points in Fig. 5 at low insulin (or
C-peptide) corresponding to low glucose samples and a
more diffuse cluster at higher insulin (or C-peptide) cor-
responding to high glucose samples. For both insulin and
C-peptide, the correlation between the results obtained
with the sensors and ELISA was outstanding (R
2  0.98
and 0.99, respectively), demonstrating the utility of the
sensors for rapid assessment of islet function. Similarly, in
randomly chosen samples from rodent islet secretion
experiments, insulin levels were determined using our
sensors and RIA assay (Fig. 6), and excellent correlation
between the two techniques was observed.
Results of experiments used to obtain basic perfor-
mance characteristics of FRET sensor assays are pre-
sented in the supplementary data. Inter- and intra-assay
precision (supplementary Tables S1–S4), spike and recov-
ery (supplementary Tables S5 and S6), assay linearity
(supplementary Tables S7 and S8), and assay cross-reac-
tivity (supplementary Tables S9 and S10) were determined
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FIG. 4. Correlation between measurements using the sensors and ELISA in 32 samples containing randomly selected concentrations of human
insulin (A) and human C-peptide (B) dissolved in a buffer.
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for ELISA.
DISCUSSION
Insulin and C-peptide sensors that we have developed
allow rapid determination of insulin and C-peptide with
high speciﬁcity and sensitivity by a procedure that requires
only the addition of the sample to the sensor mix. The
sensors exhibit sensitivity that is sufﬁcient for rapid as-
sessment of islet functionality by near-instantaneous mea-
surement of insulin or C-peptide secreted by the islets. The
use of the sensors does not require any complicated
specialized instrumentation; any standard ﬂuorescence
plate reader will be sufﬁcient.
Limits of detection that we observe with these sensors
are near the concentrations of insulin and C-peptide
observed in serum (for example, normal insulin concen-
trations in plasma are 40–160 pmol/l). However, in its
current formulation, the sensors are not yet suitable for
serum measurements. Although they do work with serum
samples (data not shown), the signiﬁcant background
ﬂuorescence produced by serum requires signiﬁcant sam-
ple dilution. In order to use these sensors for serum
measurements, the sensors will need to be further im-
proved to increase their sensitivity (5- to 10-fold) and to
reduce the background of the serum (by employing ﬂuo-
rescence probes with excitation at higher wavelength or
by using time-resolved ﬂuorescence signal detection). We
believe these improvements will be possible, and if suc-
cessful, they will widen signiﬁcantly the applicability of
our sensors. With these improvements, we envision that
the sensors could be adopted for use with a simple
handheld ﬂuorescence reader, allowing point-of-care insu-
lin and C-peptide determination.
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FIG. 6. Correlation between measurements of rat insulin using the
sensors and RIA in 15 samples from rodent islet secretion experiments.
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